RGLS - Regulus Therapeutics Inc. Net Sales Margin

Regulus Therapeutics Inc. - graphic logo of issuer RGLS

Regulus Therapeutics (RGLS) currently generates no revenue, relying instead on high-risk development and the regular issuance of new shares. The aggregate net margin clearly demonstrates this efficiency momentum, with the value stabilizing at 0.00. A team of elite geneticists is developing miRNA therapy, while anticipation of the Phase 2 trial results for the treatment of polycystic kidney disease serves as the primary growth driver.

Regulus (RGLS) Net Profit Margin: for the period 07/04/2022 - 07/05/2025

RGLS (Regulus Therapeutics): analytical breakdowns and indicator data

- market value and analyst target forecast:
- market capitalization statistics:
Fundamental company valuation:Regulus Therapeutics, Inc. - RGLS
Finished products of Regulus

Regulus Therapeutics (RGLS) is actively developing innovative RNA therapies to combat polycystic kidney disease. High clinical trial costs make financial results extremely sensitive to operating expenses. This metric determines the percentage of revenue remaining after deducting all business costs. It allows for the identification of one-time efficiency spikes and profit squeeze risks. By analyzing the net profitability chart, an investor assesses the asset's real ability to generate free income.

Competitors of Regulus Therapeutics (RGLS)

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|GBIO (generationbio.com) - Return on Sales by Net Profit|Net Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Net Sales Margin|Net Return on Sales IMNN (Imunon, Inc.)|Net Sales Margin PHIO|MBIO - Net Margin|Net Sales Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Net Margin|Applied DNA - Net Sales Margin|Net Margin Bluebird Bio|ImmunoPrecise (IPA) - Net Margin|Net Profit Margin OMGA (Omega)|Net Margin Singular Genomics Systems|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX